abstract |
The disclosed invention relates to selective VPAC1 antagonists, related formulations, dosages and methods of use. The selective VPAC1 antagonists of the invention comprise a vasoactive intestinal peptide component and a growth hormone releasing hormone component capable of selectively binding to and antagonizing the VPAC1 receptor at significantly lower concentrations than those concentrations at which it binds to and antagonizes the VPAC2 receptor. |